Welcome to our dedicated page for Halozyme Therapeutics news (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Therapeutics stock.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) is a biopharmaceutical company headquartered in San Diego, CA, focused on developing and commercializing innovative oncology therapies. The company's core mission is to enhance the efficacy of cancer treatments by targeting the tumor microenvironment, particularly through its lead investigational drug, pegph20. This drug aims to improve the penetration of co-administered cancer therapies into solid tumors, potentially making existing treatments more effective.
Halozyme's proprietary ENHANZE® drug delivery technology platform has garnered significant attention and partnerships with leading pharmaceutical companies such as Roche, Pfizer, Janssen, Baxalta, AbbVie, and Lilly. This technology facilitates the subcutaneous administration of biologics and small molecule compounds that are traditionally delivered intravenously, potentially allowing for quicker and more convenient therapy delivery.
The company has built a strong foundation of value-driving partnerships and continues to innovate in drug-device combination products using advanced auto-injector technology to improve patient convenience, comfort, and adherence. Halozyme's commercial portfolio includes proprietary products like Hylenex® and XYOSTED®, and ongoing product development in partnership with pharmaceutical companies such as Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Recent achievements highlight Halozyme’s growth and innovation. Notably, the U.S. FDA approved Takeda’s HYQVIA®, co-formulated with ENHANZE®, for the maintenance therapy of chronic inflammatory demyelinating polyneuropathy (CIDP), underscoring the potential of Halozyme’s technology to enhance treatment efficacy. Another milestone includes the Japanese Ministry of Health's approval of argenx's VYVDURA® for generalized myasthenia gravis, demonstrating global expansion and acceptance of ENHANZE®-enabled treatments.
Financially, Halozyme continues to show robust growth. The company reported strong revenue and earnings growth in the first quarter of 2024, reaffirming its positive financial guidance for the year. Halozyme also announced a new $750 million share repurchase program, indicating confidence in sustained growth.
Halozyme's efforts in maintaining an extensive patent portfolio, including the recent grant of European Patent No. 4269578 for its ENHANZE® rHuPH20 product, further solidify its market position and prospects for long-term revenue durability. The company's strategic collaborations and commitment to innovative patient solutions make it a significant player in the biopharmaceutical industry.
Halozyme Therapeutics (NASDAQ: HALO) has appointed Moni Miyashita to its board of directors, bringing over 25 years of experience in corporate strategy, mergers & acquisitions, and business transformation. The CEO, Dr. Helen Torley, expressed excitement over Miyashita's expertise, which aligns with the company's goal to expand growth opportunities. Miyashita, previously with Valo Health and IBM, aims to leverage her experience to enhance Halozyme's strategic initiatives. Halozyme is recognized for its ENHANZE® technology, improving treatment experiences for patients globally.
Halozyme Therapeutics reported robust financial results for Q4 and full year 2021, with total revenue hitting $443.3 million, a 66% increase Year-over-Year (YoY). Royalty revenue soared 130% YoY, driven mainly by the subcutaneous products DARZALEX® and Phesgo®. The company anticipates a further 50% growth in royalty revenue in 2022. Although Q4 revenue dropped to $102.0 million from $121.7 million in 2020, net income for the full year totaled $402.7 million, or $2.74 per share. Halozyme's guidance for 2022 projects revenues of $530-560 million, with a net income of $270-295 million.
Halozyme Therapeutics (NASDAQ: HALO) has announced it will host a webcast for its fourth quarter 2021 financial results on February 22, 2022, at 4:30 p.m. ET. CEO Dr. Helen Torley will lead the call, following the release of financial results after market close. Halozyme emphasizes its innovative ENHANZE® technology, which has improved treatment times for over 500,000 patients globally across five products. The company partners with major biopharmaceutical companies, generating revenue through collaborations and royalties.
Halozyme Therapeutics (NASDAQ: HALO) has promoted Nicole LaBrosse to Chief Financial Officer (CFO), succeeding Elaine Sun, who is leaving for another opportunity. LaBrosse, with over 18 years of experience, joined Halozyme in 2015 and has held progressively responsible roles, including Vice President of Finance since 2020. CEO Helen Torley expressed confidence in LaBrosse's ability to support the company's growth. Halozyme aims to improve patient experiences through its ENHANZE® technology, which streamlines treatment delivery, impacting over 500,000 patients globally.
Halozyme Therapeutics (NASDAQ: HALO) has announced its financial guidance for 2022, projecting total revenue between $530 million and $560 million, a growth of 23-26% from 2021. Royalties from products utilizing ENHANZE technology are expected to reach $300 million, a 50% increase. Operating income is forecasted at $350 million to $380 million, with a margin exceeding 65%. Key initiatives include further product development and share repurchase plans totaling up to $250 million.
Halozyme Therapeutics (NASDAQ: HALO) announced that Dr. Helen Torley, CEO, will present virtually at the 40th Annual J.P. Morgan Health Care Conference on January 10, 2022, at 7:30 a.m. PT. The conference runs from January 10-13, 2022. Interested parties can access the presentation via the Investors section of Halozyme's website. Halozyme specializes in biopharmaceutical solutions, particularly its ENHANZE® technology, which enhances drug delivery efficiency and has reached over 500,000 patients globally.
Halozyme Therapeutics (NASDAQ: HALO) has appointed Mark Snyder as the new senior vice president, general counsel, chief compliance officer, and corporate secretary, effective January 3, 2022. Snyder succeeds Masaru Matsuda, who is leaving for another opportunity. With nearly 30 years of legal and business experience, Snyder previously worked at Qualcomm, leading litigation strategies and managing legal operations. His appointment aims to enhance Halozyme's growth and shareholder value, as stated by CEO Helen Torley.
Halozyme Therapeutics has initiated a new share repurchase program, authorizing up to $750 million in buybacks over the next three years. This includes an accelerated share repurchase (ASR) of $150 million, with plans to acquire $250 million worth of shares by the end of 2022, contingent on market conditions. The program reflects Halozyme's commitment to a balanced capital allocation strategy, leveraging strong cash generation to return capital to investors while supporting growth initiatives.
Halozyme Therapeutics announced that Janssen Biotech received FDA approval for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in combination with Kyprolis (carfilzomib) and dexamethasone for adult patients with relapsed or refractory multiple myeloma. This marks the ninth indication for DARZALEX FASPRO. The approval is based on data from Janssen's PLEIADES Study, which achieved its primary endpoint of overall response rate. The product leverages Halozyme's ENHANZE technology, facilitating rapid treatment administration that may enhance patient experience.
Halozyme Therapeutics (NASDAQ: HALO) will participate in two upcoming investor conferences:
- 33rd Annual Piper Sandler Virtual Healthcare Conference on November 22, 2021, featuring Elaine Sun in an on-demand chat.
- Evercore ISI 4th Annual HealthCONx Conference on December 1, 2021, with Dr. Helen Torley representing the company in a virtual chat.
Presentations can be accessed via the investors section of Halozyme.com, with recordings available for six months.
FAQ
What is the current stock price of Halozyme Therapeutics (HALO)?
What is the market cap of Halozyme Therapeutics (HALO)?
What is Halozyme Therapeutics' main focus?
What is the ENHANZE® technology?
Who are Halozyme's key partners?
What recent approvals have Halozyme's technologies received?
What are some of Halozyme's proprietary products?
Where is Halozyme headquartered?
How does Halozyme's ENHANZE® technology benefit patients?
What is the significance of Halozyme's recent European patent grant?
What financial outlook did Halozyme recently provide?
What is pegph20?
